Extrapolation as a Default Strategy in Pediatric Drug Development

Area of Science:

• Pharmacology
• Pediatric Medicine
• Drug Development

Background:

• Pediatric drug development significantly lags behind adult drug development, creating a disparity in treatment options for children.
• Existing strategies to address this gap include incentives, regulations, and innovative techniques like extrapolation of efficacy data from adult populations.

Purpose of the Study:

• To advocate for the initial assumption of extrapolation in pediatric drug development programs, despite inherent uncertainties.
• To propose a framework where the degree of extrapolation is a continuum, guided by the need to address uncertainties with pediatric evidence.

Main Methods:

• Conceptual analysis and position paper based on existing literature and regulatory considerations.
• Discussion of extrapolation as a strategy, emphasizing the continuum of uncertainty and the generation of pediatric evidence.

Main Results:

• The paper posits that pediatric drug development should begin with an assumption of extrapolation.
• The extent of extrapolation should be determined by the level of tolerable uncertainty, considering the risks of exposing children to new drugs.

Conclusions:

• The strategy for extrapolation must be context-dependent, varying with disease severity and available therapies.
• Integrating judgments about tolerable uncertainty into pediatric drug development archetypes can guide study design and consider simultaneous adult and adolescent development.